Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

New International Study Highlights IOP-Lowering Performance Of Glaukos iStent Inject® Trabecular Micro-Bypass In Standalone Procedure

November 8, 2016 By the Associated Press

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that in a study published in Advances in Therapy, 100% of 57 phakic eyes with open-angle glaucoma achieved a ≥ 20% reduction in unmedicated intraocular pressure (IOP) one year after implantation of the iStent inject®Trabecular Micro-Bypass in a standalone procedure. Phakic refers to eyes that have not undergone prior cataract surgery and have a natural lens.
The iStent inject is a second-generation Micro-Invasive Glaucoma Surgery (MIGS) device that includes two stents preloaded into an auto-injection mechanism. It allows an ophthalmic surgeon to inject the stents from within the eye’s anterior chamber through the trabecular meshwork and into Schlemm’s canal, the eye’s drainage canal. Once in place, the stents are designed to reduce IOP by restoring the natural outflow pathways for aqueous humor.

The study was conducted at a single international site, where 11 surgeons performed the 57 iStent inject procedures. Study researchers reported a high safety profile and plan to follow subjects through five years. Additional study findings at one year postoperative included: All eyes had IOP ≤ 18 mm Hg and 67% of eyes had IOP ≤ 15 mm Hg without medication vs. preoperative unmedicated IOP between 22-38 mm Hg. Mean unmedicated IOP was 14.2 mm Hg, a 42% reduction from preoperative mean unmedicated IOP of 24.4 mm Hg; this reduction was maintained through 18 months.

“Our data suggest that second-generation trabecular stents, implanted as a sole procedure, can achieve sustained IOP and medication reductions in open-angle glaucoma patients,” said Richard Lindstrom, MD, who authored the study. “These outcomes are promising because they underscore the potential for iStent inject to be a viable alternative to open-angle glaucoma patients’ chronic use of topical ocular hypotensive medications, which often require complex dosing regimens, have multiple side effects and can be ineffective due to high rates of non-compliance.”

The iStent inject uses the same fluidic mechanism of action as the first-generation iStent® Trabecular Micro-Bypass, which was approved by the U.S. Food & Drug Administration (FDA) in 2012 for use in conjunction with cataract surgery. Made of surgical-grade non-ferromagnetic titanium that is coated with heparin, the iStent is approximately 1.0 mm long and 0.33 mm wide. The iStent inject is approximately one-third the size of iStent and is for investigational use only in the United States, with two IDE clinical trials underway for two versions of the product, one for use in conjunction with cataract surgery and another for use as a standalone procedure.

In the European Union and Canada, iStent inject is approved for use either in combination with cataract surgery or as a standalone procedure. It is also approved for use in combination with cataract surgery in Australia.

Typically associated with elevated IOP, glaucoma is characterized by progressive, irreversible and largely asymptomatic vision loss caused by optic nerve damage. It is a leading cause of blindness. According to Market Scope, more than 80 million people worldwide have glaucoma, including 4.5 million people in the United States. Open-angle glaucoma is the most common form, affecting approximately 3.6 million people in the United States.

 

Related Articles Read More >

A portrait of ResMed President and COO Rob Douglas
ResMed finds a solution to semiconductor shortage, as well as some humor in it
Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech